Ï㽶ÊÓƵ

Ashley Wazana

Academic title(s): 

Associate Professor

Contact Information
Email address: 
ashley.wazana [at] mcgill.ca
Phone: 
514-340-8210
Fax number: 
514-340-7903
Address: 

Center for Child Development and Mental Health, Jewish General Hospital
4335 Cote Ste-Catherine Road - M012
Montreal, Quebec
H3T 1E4

Degree(s): 

MD, FRCP, MSc

Areas of expertise: 

Child psychiatry, developmental psychopathology, gene by environment interactions

Biography: 

Dr. Ashley Wazana is a clinician-scientist in the department of psychiatry at the Jewish General Hospital. He was trained as a child psychiatrist at McGill and as an epidemiologist at Columbia University. He is the clinical and research director of an Early Childhood Disorders day hospital at the Jewish General Hospital as well as an investigator in projects at the Lady Davis Institute for Medical Research, at the Douglas Institute of Mental Health and in international collaborations with France, Finland the United States. He currently holds the McGill Chair of Psychiatry's Early Career Researcher Award. Dr. Wazana is currently the Principal Investigator for the psychiatric outcomes of Dr Michael Meaney's Maternal Adversity, Vulnerability and Neurodevelopment (MAVAN) project. His CIHR and March of Dimes funded project aims to identify how genotypes in the Serotonin, Dopamine and Glucocorticoid pathways and which early maternal experiences interact to modify the trajectory for anxious and depressive psychopathology of children with prenatal adversity. Low birth weight and prenatal maternal depression are two conditions of adversity used to test competing models of developmental psychopathology about the role of prenatal experience (determinants or susceptibility-factors). He is also faculty in the McGill Division of Social and Transcultural Psychiatry and is involved in a community-based intervention to prevent maladjustment of Aboriginal youth. He has also been extensively involved in research, teaching and policy development in the relation between physicians and the pharmaceutical industry, a domain for which he has been called to testify as an expert witness. He was a member of the Consensus Panel which developed the AACAP's recent conflict of interest guidelines. He is currently the chair of the Research and Scientific Program committee of the Canadian Academy of Child and Adolescent Psychiatry.

Back to top